Cargando...
Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis
BAY 94-9027 (damoctocog alfa pegol, Jivi) is an extended-half-life recombinant factor VIII (rFVIII) shown to be well-tolerated and efficacious in bleeding prevention in previously treated patients with severe hemophilia A. During the PROTECT VIII study, prophylaxis patients received BAY 94-9027 at i...
Guardado en:
| Publicado en: | Thromb Haemost |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Georg Thieme Verlag KG
2021
|
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8322588/ https://ncbi.nlm.nih.gov/pubmed/33296943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/a-1333-5536 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|